ABCB6 and colorectal carcinoma: In the last few years, pharmacogenomics has largely been applied to the personalization of CRC treatment, specifically focusing on the genetic variability in ADME genes (De Mattia et al., 2015) demonstrating the role of genetic markers in UGT1A and ABC, and SLC transporters, in combination with clinico-demographic features, in predicting FOLFIRI toxicity (Toffoli et al., 2006; Cecchin et al., 2009; Toffoli et al., 2010; De Mattia et al., 2013a; Levesque et al., 2013; Chen et al., 2015a,b).